Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Sonrotoclax Plus Zanubrutinib vs Placebo Plus Zanubrutinib in Relapsed/Refractory Mantle Cell Lymphoma
jRCT2031250097Phase 3Recruiting
- Sponsor
- BeOne Medicines
- Start
- Sep 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in mantle cell lymphoma (MCL) comparing Sonrotoclax + Zanubrutinib with Placebo + Zanubrutinib (2 arms). Primary endpoint: Progression-free survival. Started Sep 2025; status: recruiting.
02
Drugs
sonrotoclax
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on jRCT2031250097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250097.